Calendar

Week of Apr 27, 2026

Apr 30, 2026phase 2 completion106d agoAustralasian Gastro-Intestinal Trials Group — valproate sodium (Phase II Trial Completion)VALPROATE SODIUM

Therapy area: Oncology. Indication: Colorectal Cancer, Metastatic Colorectal Cancer

full page →VALPROATE SODIUM →source: globaldata

Apr 30, 2026phase 2 completion106d agoZhejiang University Hospital One — serplulimab (Phase II Trial Completion)serplulimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →serplulimab →source: globaldata

Apr 30, 2026phase 2 completion106d agoGerman Sport University Cologne — polyphenol-rich cocoa extract (Phase II Trial Completion)polyphenol-rich cocoa extract

Therapy area: Cardiovascular. Indication: Idiopathic (Essential) Hypertension

full page →polyphenol-rich cocoa extract →source: globaldata

Apr 30, 2026phase 2 completion106d agoGuangzhou Panyu Central Hospital — aumolertinib mesylate (Phase II Trial Completion)aumolertinib mesylate

Therapy area: Oncology. Indication: Lung Adenocarcinoma, Non-Small Cell Lung Cancer

full page →aumolertinib mesylate →source: globaldata

Apr 30, 2026phase 2 completion106d agoMedanta - The Medicity — centhaquine citrate (Phase II Trial Completion)centhaquine citrate

Therapy area: Cardiovascular, Other Diseases. Indication: Hemorrhagic Shock, Injury, Trauma

full page →centhaquine citrate →source: globaldata

Apr 30, 2026phase 2 completion106d agoSun Yat-Sen University Hospital 5 — carboplatin (Phase II Trial Completion)Carboplatin Pfizer

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)

full page →Carboplatin Pfizer →source: globaldata

Apr 30, 2026phase 2 completion106d agoAssaf Harofeh Medical Center — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System. Indication: Pain

full page →acetaminophen ER →source: globaldata

Apr 30, 2026phase 2 completion106d agoShanghai Longfine Biotechnology Co Ltd — toripalimab (Phase II Trial Completion)toripalimab

Therapy area: Oncology. Indication: Triple-Negative Breast Cancer (TNBC)

full page →toripalimab →source: globaldata

Apr 30, 2026phase 2 completion106d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — lenvatinib (Phase II Trial Completion)lenvatinib

Therapy area: Cardiovascular, Oncology. Indication: Hepatocellular Carcinoma, Thrombosis, Venous (Vein) Thrombosis

full page →lenvatinib →source: globaldata

Apr 30, 2026phase 2 completion106d agoMedical University of Gdansk — apixaban (Phase II Trial Completion)apixaban ODT

Therapy area: Cardiovascular, Oncology. Indication: Diffuse Large B-Cell Lymphoma, Hematological Tumor, Leukemia, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Pulmonary Embolism, Thromboembolic Disease, Venous Thromboembolism

full page →apixaban ODT →source: globaldata

Apr 30, 2026phase 2 completion106d agoNeurodawn Pharmaceutical Co Ltd — Loberamisal (Phase II Trial Completion)Loberamisal

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Cerebral Infarction (Brain Infarction)

full page →Loberamisal →source: globaldata

Apr 30, 2026phase 2 completion106d agoXijing Hospital — pertuzumab + trastuzumab (Phase II Trial Completion)pertuzumab + trastuzumab

Therapy area: Oncology. Indication: Breast Cancer, Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer), Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Triple-Negative Breast Cancer (TNBC)

full page →pertuzumab + trastuzumab →source: globaldata

Apr 30, 2026phase 2 completion106d agoSohag University — ephedrine (Phase II Trial Completion)ephedrine

Therapy area: Cardiovascular. Indication: Hypotension

full page →ephedrine →source: globaldata

Apr 30, 2026phase 2 completion106d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata

Apr 30, 2026phase 2 completion106d agoCurtin University — influenza vaccine (Phase II Trial Completion)influenza vaccine

Therapy area: Cardiovascular. Indication: Myocardial Infarction

full page →influenza vaccine →source: globaldata

Apr 30, 2026phase 2 completion106d agoBeijing Sanbo Brain Hospital — ceritinib (Phase II Trial Completion)ceritinib

Therapy area: Oncology. Indication: Mesenchymal Tumor

full page →ceritinib →source: globaldata

Apr 30, 2026phase 2 completion106d agoWuhan Union Hospital — cadonilimab (Phase II Trial Completion)cadonilimab

Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer), Metastatic Breast Cancer, Triple-Negative Breast Cancer (TNBC)

full page →cadonilimab →source: globaldata

Apr 30, 2026phase 2 completion106d agoBeijing Jishuitan Hospital — undisclosed anesthetic drug (Phase II Trial Completion)undisclosed anesthetic drug

Therapy area: Central Nervous System, Musculoskeletal Disorders. Indication: Bone Fracture, Pain

full page →undisclosed anesthetic drug →source: globaldata

Apr 30, 2026phase 2 completion106d agoOhio State University Comprehensive Cancer Center — canakinumab (Phase II Trial Completion)canakinumab

Therapy area: Oncology. Indication: Lung Cancer

full page →canakinumab →source: globaldata

Apr 30, 2026phase 2 completion106d agoNational Cancer Institute US — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Endometrial Cancer

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion106d agoBioCanRx — ipilimumab (Phase II Trial Completion)ipilimumab

Therapy area: Oncology. Indication: Kidney Cancer (Renal Cell Cancer), Metastatic Renal Cell Carcinoma

full page →ipilimumab →source: globaldata

Apr 30, 2026phase 2 completion106d agoChinese Academy of Medical Sciences and Peking Union Medical College — fuzuloparib (Phase II Trial Completion)fuzuloparib

Therapy area: Oncology. Indication: Soft Tissue Sarcoma

full page →fuzuloparib →source: globaldata

Apr 30, 2026phase 2 completion106d agoSun Pharmaceutical Industries Ltd — Absorica (Phase II Trial Completion)ISOTRETINOIN

Therapy area: Oncology. Indication: Neuroblastoma

full page →ISOTRETINOIN →source: globaldata

Apr 30, 2026phase 2 completion106d agoDutch Heart Foundation — ghrelin (Phase II Trial Completion)ghrelin

Therapy area: Cardiovascular. Indication: Acute Ischemic Stroke, Ischemic Stroke

full page →ghrelin →source: globaldata

Apr 30, 2026phase 2 completion106d agoArcus Biosciences Inc — atezolizumab (Phase II Trial Completion)atezolizumab

Therapy area: Oncology. Indication: Prostate Cancer

full page →atezolizumab →source: globaldata

Apr 30, 2026phase 2 completion106d agoHospital Of Dalian Medical University 1 — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Adenocarcinoma Of The Gastroesophageal Junction, Gastric Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion106d agoCancer Institute and Hospital Chinese Academy of Medical Sciences — capecitabine (Phase II Trial Completion)capecitabine

Therapy area: Oncology. Indication: Colorectal Cancer

full page →capecitabine →source: globaldata

Apr 30, 2026phase 2 completion106d agoNanfang Hospital of Southern Medical University — adebrelimab (Phase II Trial Completion)adebrelimab

Therapy area: Oncology. Indication: Small-Cell Lung Cancer

full page →adebrelimab →source: globaldata

Apr 30, 2026phase 2 completion106d agoPolice General Hospital — acetaminophen (Phase II Trial Completion)acetaminophen ER

Therapy area: Central Nervous System, Women's Health. Indication: Labor And Delivery, Pain

full page →acetaminophen ER →source: globaldata

← prev

page 3 of 3

Week of Apr 27, 2026